Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 4

GENEREX BIOTECHNOLOGY CORP

Form 4 January 04, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue.

See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

GENEREX BIOTECHNOLOGY

(Print or Type Responses)

1(b).

(Last)

202

Common

Stock

1. Name and Address of Reporting Person *

FLETCHER MARK

(First)

(Middle)

33 HARBOUR SQUARE, SUITE

(Street)

TORONTO ONTARIO CANADA, A1 M5J2G2

3235-0287 Number:

January 31,

2005

OMB APPROVAL

Expires:

OMB

Estimated average burden hours per 0.5

response...

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

Director 10% Owner X_ Officer (give title Other (specify

below) EVP & General Counsel

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if Security (Instr. 3)

01/04/2010

(Month/Day/Year)

Symbol

CORP [GNBT]

(Month/Day/Year)

Filed(Month/Day/Year)

3.

P

01/04/2010

3. Date of Earliest Transaction

4. If Amendment, Date Original

Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5)

Code V Amount (D)

(A)

or

4. Securities Acquired 5. Amount of Securities Beneficially Owned **Following** Reported

(D) or Indirect (I) (Instr. 4)

Form: Direct Indirect Beneficial Ownership (Instr. 4)

(9-02)

6. Ownership 7. Nature of

Transaction(s) (Instr. 3 and 4) Price

266,077 D 8,700

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 4

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transactio	5. Mumber	6. Date Exercisable and Expiration Date		7. Title and Amount of		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(монил дау/ теаг)	any (Month/Day/Year)	Code (Instr. 8)	of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			Underlyin Securities (Instr. 3 a	ng s	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	or Title Nu of	umber		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

FLETCHER MARK 33 HARBOUR SQUARE SUITE 202 TORONTO ONTARIO CANADA, A1 M5J2G2

EVP & General Counsel

Signatures

Reporting Person

/s/ Mark

Fletcher 01/04/2010

**Signature of Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2